MODEL VERDICT
Sangamo Therapeutics, Inc. (SGMO)
Relative Valuation•Peer multiples, Monte Carlo simulation & quality-adjusted fair value
Popular:
Composite score derived from valuation, quality, and risk factors
Quantitative model thresholds · For educational and research purposes only
| Methodology | Fair Value | vs Current | Weight | Quality | Status |
|---|---|---|---|---|---|
| EV To Revenue 182 industry peers | $1.52 | +280.0% | 4% | B | Data |
| Price / Sales 184 industry peers | $1.38 | +245.0% | 3% | B | Model Driven |
| Weighted Output Blended model output | $1.35 | +237.5% | 100% | 66 | SIGNIFICANTLY UNDERVALUED |
Cross-sectional regression predicting expected multiples based on growth, margins, ROIC, and beta.
| Multiple | Avg | Median | Min | Max | Std |
|---|---|---|---|---|---|
| P/TBV | 4.07 | 3.85 | 1.14 | 9.04 | 2.56 |
| P/B Ratio | 3.45 | 2.89 | 1.14 | 9.04 | 2.66 |
| P/S Ratio | 8.33 | 9.16 | 0.54 | 17.75 | 5.98 |
Based on our peer multiples analysis with 5 valuation metrics, the model estimates SGMO's fair value at $1.35 vs the current price of $0.40, implying +237.5% upside potential. Model verdict: Significantly Undervalued. Confidence: 66/100. This is a quantitative estimate, not a recommendation.
The blended fair value of $1.35 is calculated using four lenses: industry median multiples (40%), historical multiples (30%), forward estimates (20%), and quality-adjusted multiples (10%). Monte Carlo simulation (10,000 iterations) gives a range of $0.77 (P10) to $2.18 (P90), with a median of $1.46.
SGMO's current P/E of -0.8x compares to the industry median of 23.5x (45 peers in the group). This represents a -103.5% discount to the industry. The historical average P/E is N/Ax over 0 years. Signal: Deep Discount.
14 analysts cover SGMO with a consensus rating of Hold. The consensus price target is $7.25 (range: $2.00 — $19.00), implying +1712.5% upside from the current price. Grade breakdown: Strong Buy (0), Buy (6), Hold (7), Sell (1), Strong Sell (0).
The model confidence score is 66/100, based on: data completeness (6), peer quality (25), historical depth (20), earnings stability (5), and model agreement (10). Cyclicality penalty: -0 points. The model shows moderate agreement across inputs.
The model flags several key risks: (1) Macro/regulatory risks are not captured in this model but remain material.
Peak earnings risk data is not available for SGMO.
No. This dashboard is a quantitative research tool for educational and informational purposes only. It is not investment advice, a solicitation, or a recommendation to buy, sell, or hold any security. The operator of this platform is not a registered investment advisor (RIA), broker-dealer, or financial planner. All model outputs, fair value estimates, signals, and scenarios are the result of automated quantitative computations and should not be construed as professional financial guidance. You should consult a qualified, licensed financial advisor before making any investment decisions. Past model performance is not indicative of future results.